Abstract

SMAD4SMAD4 gene, which renders the cell resistant to the immunosuppressive effects of TGF-β and allows it to maintain its cytotoxicity. Additionally, a cell population and a pharmaceutical composition comprising the modified human cytotoxic lymphocyte cell are also provided, which are useful in the treatment of cancer. Particularly, it is provided modified NK cells for an off- the-shelf treatment.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Rothia nasimuriumRothia nasimurium Rothia nasimuriumRothia nasimuriumRothia nasimuriumRothia nasimuriumRothia nasimurium, or immunomodulatory fraction thereof, and the use of said composition in the prevention and/or treatment of African Swine Fever (ASF).

IPC Classes  ?

• A61K 39/05 - CorynebacteriumPropionibacterium
• A61K 39/12 - Viral antigens
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention relates to a viral expression construct and related viral vector and composition and to their use wherein said construct and vector comprise elements a) and b): a) a nucleotide sequence encoding an insulin operably linked to a first promoter, b) a nucleotide sequence encoding a glucokinase operably linked to a second promoter and said viral expression construct and related viral vector comprise at least one of elements c), d) and e): c) the first and the second promoters are positioned in reverse orientation within the expression construct, d) the first and the second promoters are positioned in reverse orientation within the expression construct and are located adjacent to each other and e) the first promoter is a CMV promoter, preferably a mini CMV promoter.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/28 - Insulins
• A61K 38/45 - Transferases (2)
• C07K 14/62 - Insulins
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/86 - Viral vectors

Abstract

Described herein are recombinant viral genomes comprising a nucleotide sequence encoding a telomerase reverse transcriptase (TERT) operably linked to a tissue-specific and/or organ-specific promoter. Aspects described herein may be used in the treatment of conditions associated with shortened telomere length, such as pulmonary fibrosis, myocardial infarction and conditions associated therewith.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to a multilayer material, comprising a solid substrate coated at least partially with a textured α-quartz buffer layer, the crystallographic direction of the α-quartz being parallel to the crystallographic direction of the silicon; and on said α-quartz buffer layer, a layer of one-dimensional epitaxial ZnO microcrystals (or epitaxial ZnO microwires), said microcrystals being self-assembled. The present invention also relates to a method for producing such a multilayer material, as well as to the industrial use thereof in various technical fields.

IPC Classes  ?

• C30B 29/62 - Whiskers or needles
• C30B 5/00 - Single-crystal growth from gels
• C30B 7/00 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
• C30B 7/10 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by application of pressure, e.g. hydrothermal processes
• C30B 7/14 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
• C30B 29/16 - Oxides
• H03H 9/17 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator
• H03H 9/19 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator consisting of quartz

Abstract

The present invention provides new polynucleotide sequences, adeno-associated virus-derived vectors and pharmaceutical compositions containing the same for the treatment of lysosomal storage disorders and specially, for the treatment of mucopolysaccharidosis type IVA or Morquio A syndrome.

IPC Classes  ?

• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/86 - Viral vectors

Abstract

A benzophenone compound of formula (I) and the pharmaceutically salts thereof are provided, which are useful in the treatment of a transthyretin amyloidosis. The compound presents higher affinity to transthyretin, higher bioavailability and reduced toxicity. A process for preparing the compound and a pharmaceutical composition comprising the compound are also provided.

IPC Classes  ?

• C07C 205/45 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by at least one doubly-bound oxygen atom, not being part of a —CHO group
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and/or treatment of cognitive and/or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

The present invention relates to a piezoelectric, epitaxially grown pseudosubstrate comprising a silicon wafer (100) having two parallel faces, and a thin layer of α-quartz (100) grown epitaxially on one of the faces of said wafer, said thin α-quartz layer (100) exhibiting a uniform crystallization with a mosaicity around the peak (100) of the quartz of between 6° and 1° and a thickness of between 100 nm and 1 μm. The present invention also relates to a process for fabricating such a pseudosubstrate, and to the use thereof for producing piezoelectric membranes.

IPC Classes  ?

• C30B 29/18 - Quartz
• C30B 1/02 - Single-crystal growth directly from the solid state by thermal treatment, e.g. strain annealing
• H03H 3/02 - Apparatus or processes specially adapted for the manufacture of impedance networks, resonating circuits, resonators for the manufacture of electromechanical resonators or networks for the manufacture of piezoelectric or electrostrictive resonators or networks
• H03H 9/19 - Constructional features of resonators consisting of piezoelectric or electrostrictive material having a single resonator consisting of quartz

Abstract

The present invention provides a polypeptide having disaggregase activity for use in medicine, wherein the polypeptide comprises the sequence SEQ ID NO: 1 or SEQ ID NO: 2, or a variant thereof that retains the disaggregase activity, more particularly for use in the prevention or treatment of a disease or disorder associated with protein aggregates in a subject. The invention also provides an expression vector encoding the polypeptide for the same use, and uses and methods for eliminating or preventing the formation of a protein aggregate in a protein-containing composition. The invention also provides the use of the polypeptide for imaging a protein aggregate and for the diagnosis and prognosis of a disease associated with protein aggregates.

IPC Classes  ?

• C12N 9/50 - Proteinases
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)

Abstract

The present invention relates to a fusion protein comprising sTREM2 or a functional variant thereof; TIMP2 or a functional variant thereof; and sKL or a functional variant thereof. The invention also relates to a polynucleotide, an expression vector, a host cell, and a pharmaceutical composition encoding or comprising the fusion protein. Furthermore, the invention relates to the fusion protein for use as a medicament, particularly for use in the prevention or treatment of an age-related disease or disorder, and more particularly an age-related neurodegenerative disease or disorder.

IPC Classes  ?

• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/81 - Protease inhibitors
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

The present invention relates to a cholecystokinin (CCK) antagonist for use in the prevention and/or treatment of a vestibular disease or disorder selected from motion sickness, Meniere's disease, vestibular migraine, disembarkment sickness, labyrinthitis, vestibular neuronitis, benign paroxysmal positional vertigo, and labyrinthine infarction. It also relates to a drug combination comprising a CCK antagonist and a GLP1 receptor agonist, to compositions comprising this combination, and to a CCK antagonist for use in the treatment and/or prevention of adverse side effects associated to a GLP1 receptor agonist, in a subject undergoing therapy with a GLP1 receptor agonist.

IPC Classes  ?

• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 31/425 - Thiazoles
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
• A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
• A61P 27/00 - Drugs for disorders of the senses

Abstract

The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and/or treatment of cognitive and/or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)

Abstract

outoutoutout(t) (112) into the low-pass-filtered intramodulator feedback signal (110).

IPC Classes  ?

• H03M 3/00 - Conversion of analogue values to or from differential modulation

Abstract

A device for performing an assay system, the device including a chamber comprising a first opening, and a second opening; a liquid exit; a liquid absorbing pad adjacent to the chamber; an opening assembly for shifting the device between a closed position and an open position; a sealing element; wherein: in the closed position the sealing element covers the liquid exit such that a liquid is prevented from flowing out of the chamber; and in the open position at least part of the liquid exit is uncovered by the sealing element and the device comprises a fluidic path between the chamber and the liquid absorbing pad through the uncovered part of the liquid exit.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

A polypeptide consisting of sequence SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and/or treatment of a bone disorder. The nucleic acid sequence that encodes the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector may be administered in the form of a pharmaceutical composition together with at least one pharmaceutically acceptable excipient, diluent or carrier.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• C12N 15/86 - Viral vectors

Abstract

The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for delivery of the same for treating diabetes.

IPC Classes  ?

• C07K 14/62 - Insulins
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07K 14/54 - Interleukins [IL]
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/86 - Viral vectors

Abstract

A method, system and computer programs for characterization of cancer are provided. The method comprises accessing or receiving image data and clinical and demographic data and/or genomic information, the image data including different types of CT scans of a subject, and the clinical and demographic data including attributes of a group of subjects; computing radiomic features using a feature extraction algorithm and embedding the computed radiomic features and the clinical and demographic data and/or genomic information in an abstract space representing the lesion; performing a characterization of the lesion at different levels by determining categorical and quantitative variables associated to each level using the computed radiomic features, providing a multi-diagnostic and/or -prognostic characterization of the lesion as a result; and translating the provided multi-diagnostic and/or -prognostic characterization of the lesion into radiological words or annotations that quantitatively and/or qualitatively describe the lesion using a multi-attention transformer.

IPC Classes  ?

• G06F 18/2413 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on distances to training or reference patterns
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G06T 7/00 - Image analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

Protein nanopellets for fish or teleost and crustacean vaccination The present invention relates to protein nanopellets comprising one or more polypeptides comprising the amino acid sequence of an interferon or a fragment thereof, the amino acid sequence of a viral antigen or a fragment thereof and, optionally, a linker between them; and with a particle diameter from 400 nm to 1500 nm, measured by electron microscopy. It also discloses their use in immunogenic compositions and vaccines to immunize fish or teleost and crustacean against several virus diseases.

IPC Classes  ?

• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
• A61K 38/19 - CytokinesLymphokinesInterferons
• A61K 39/12 - Viral antigens
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/52 - CytokinesLymphokinesInterferons
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The invention relates to a viral expression construct and related viral vector and nucleic acid molecule and composition and to their use wherein said construct and vector are suitable for expression in a mammal and comprise a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) to be expressed in liver, adipose tissue and/or skeletal muscle.

IPC Classes  ?

• C07K 14/50 - Fibroblast growth factor [FGF]
• A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic
• A61K 35/761 - Adenovirus
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to the medical field, in particular, to a nanotechnological based Enzyme Replacement Therapy, preferably for Parkinson's disease, based on the restoration of lysosomal glucocerebrosidase activity through enzyme-polymer nanoconjugation of GBA, the GBA polymer conjugate for such use, and its manufacturing method.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention provides a polypeptide consisting of sequence SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in extending the lifespan of a subject. The invention also provides nucleic acid sequence that encodes the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the invention may be administered in the form of a pharmaceutical composition together with at least one pharmaceutically acceptable excipient, diluent or carrier.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases

Abstract

The present invention provides a polypeptide consisting of sequence SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and/or treatment of a muscle disease or disorder. The invention also provides nucleic acid sequence that encodes the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the invention may be administered in the form of a pharmaceutical composition together with at least one pharmaceutically acceptable excipient, diluent or carrier. The invention also provides a non-therapeutic method for improving muscle function and/or increasing muscle mass of a subject.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 21/06 - Anabolic agents
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators

Abstract

The present invention relates to materials with thermoregulable light transmittance; in particular, to a thermoresponsive transmittance composition comprising: (I) one or more polymers; (ii) one or more phase change materials (PCM); (iii) optionally, one or more photothermal agents capable of absorbing visible and/or near-infrared radiation (NIR) and converting the visible and/or NIR radiation into heat; (iv) optionally, one or more electroheaters; and (v) optionally, one or more excipients or carriers. These compositions are capable of changing from a light transparent state to a light non-transparent state upon temperature variation generated by external heat, light irradiation and/or voltage application. The invention also discloses free-standing films and articles containing the thermoresponsive transmittance compositions, as well as the processes for their preparation and their uses therefore, such as in optics as smart glass.

IPC Classes  ?

• G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
• C09K 9/02 - Organic tenebrescent materials
• G02B 1/00 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements

Abstract

The present invention relates to an antioxidant compound which is 10-(6'- Plastoquinonyl)decyltriphenylphosphonium (SkQ1) for use in the prevention and/or treatment of the detrimental effect caused by natural or induced aging of the ovarian reserve of a female mammal.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/05 - Phenols
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/66 - Phosphorus compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A61P 15/12 - Drugs for genital or sexual disordersContraceptives for climacteric disorders

Abstract

The present invention relates to the field of nanostructured protein materials, more specifically to therapeutic agents carrying fusion proteins which can be used for therapy.

IPC Classes  ?

• C07K 14/49 - Platelet-derived growth factor [PDGF]
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.

IPC Classes  ?

• A01K 67/0278 - Knock-in vertebrates, e.g. humanised vertebrates
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding an alpha subunit of a beta-hexosaminidase, a nucleotide sequence encoding a peptide linker, and a nucleotide sequence encoding a beta subunit of a beta-hexosaminidase. Aspects and embodiments described herein may be used in the treatment of GM2 gangliosidoses, including Tay-Sachs and Sandhoff disease.

IPC Classes  ?

• C12N 15/86 - Viral vectors

Abstract

The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

The present invention relates to compounds of formula (I) The present invention relates to compounds of formula (I) AA1-AA2-D-Ile-AA3-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D- Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 (I) or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/86 - Viral vectors

Abstract

Present invention relates to a new podocyte-specific hybrid promoter and to gene constructs comprising it. The invention encompasses also new pharmaceutical compositions. All of them are for use as medicaments, in particular for use in the prevention and/or treatment of kidney diseases.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/86 - Viral vectors
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present disclosure provides gene constructs containing a nucleic acid sequences encoding a mammalian s-KL, operatively linked to a muscle cell-specific promoter, for use in the treatment of motor impairment that may manifest, for example, in a neuromuscular disorder or disease, utilizing viral and non-viral vectors with muscle cell and motor neuron tropisms containing gene constructs containing a nucleic acid sequence encoding a mammalian s-KL, operatively linked to a promoter such as a muscle cell-specific promoter, is delivered in pharmaceutical compositions containing the expression vector, isolated cells containing the expression vector, and methods of treating motor impairment and motor neuron diseases.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C12N 15/86 - Viral vectors

Abstract

The present invention generally relates to inhibitors of α-synuclein aggregation which are characterized by comprising an amphipathic α-helical peptide. The invention further relates to therapeutic and diagnostic uses of such inhibitors as well as corresponding plasmonic sensors, kits, and pharmaceutical compositions.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A method for concentrating or dehydrating liquid food products is provided. The method comprises using an electrospraying technique on a liquid food product, the electrospraying technique including the application of an electrical potential, comprised in a range between 20 kV and 50 kV, on the liquid food product using an injection needle, obtaining a concentrated or dehydrated product as a result, the distance between said injection needle and a collector used for collecting the concentrated or dehydrated product being between 10 cm and 50 cm. The invention also relates to the use of an electrospraying technique to concentrate or dehydrate a liquid food product.

IPC Classes  ?

• A23C 1/00 - Concentration, evaporation or drying
• A23C 9/00 - Milk preparationsMilk powder or milk powder preparations
• B05D 1/04 - Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field

Abstract

The invention relates to an immunogenic composition comprising or consisting of a particle with a particular hydrodynamic diameter, said particle comprising self-assembled protein and/or peptide molecules and one or more salts of divalent cations. The invention also relates to vaccines comprising the immunogenic composition and to their use in the prevention and/or treatment of diseases.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 9/51 - Nanocapsules

Abstract

The present disclosure provides gene constructs containing a nucleic acid sequences encoding a mammalian s-KL, operatively linked to a muscle cell-specific promoter, for use in the treatment of motor impairment that may manifest, for example, in a neuromuscular disorder or disease, utilizing viral and non-viral vectors with muscle cell and motor neuron tropisms containing gene constructs containing a nucleic acid sequence encoding a mammalian s-KL, operatively linked to a promoter such as a muscle cell-specific promoter, is delivered in pharmaceutical compositions containing the expression vector, isolated cells containing the expression vector, and methods of treating motor impairment and motor neuron diseases.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/861 - Adenoviral vectors

Abstract

The present disclosure provides gene constructs containing a nucleic acid sequences encoding a mammalian s-KL, operatively linked to a muscle cell-specific promoter, for use in the treatment of motor impairment that may manifest, for example, in a neuromuscular disorder or disease, utilizing viral and non-viral vectors with muscle cell and motor neuron tropisms containing gene constructs containing a nucleic acid sequence encoding a mammalian s-KL, operatively linked to a promoter such as a muscle cell-specific promoter, is delivered in pharmaceutical compositions containing the expression vector, isolated cells containing the expression vector, and methods of treating motor impairment and motor neuron diseases.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C12N 15/861 - Adenoviral vectors

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a central nervous system (CNS) disorder or disease, or a condition associated therewith.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• C12N 15/86 - Viral vectors
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention provides a method for determining the resistance of a microorganism to a drug by detecting at least a transcript of a drug resistance gene from a microorganism in a biological sample, the method comprising the steps of: (i) lysing the cells by means of a chemical or a mechanical method, thereby obtaining a lysate and cell debris; (ii) obtaining a ribosome-antibody complex from the lysate using an antibody or a fragment thereof which binds specifically to a microorganism-ribosomal protein; (iii) purifying the mRNA associated to the ribosome-antibody complex by means of a nucleic acid extraction method; and (iv) submitting the resulting mRNA to a specific gene detection method, thereby identifying the at least one drug resistance gene transcript of the biological sample. Provided methods and kits allow determining the resistance to antibiotics of a biological sample in a rapid and reliable manner, thereby minimizing the risk of AMR and allowing the definition of the therapeutic potential of a selected antibiotic

IPC Classes  ?

• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12Q 1/6804 - Nucleic acid analysis using immunogens

Abstract

The present invention relates to a compound selected from the group consisting of of N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide, [2-(2,6-dichloroanilino)-4,5-dihydroimidazol-1-yl]-phenylmethanone, 2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one, N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide and 2-(1,4-dioxaspiro[4.5]decan-2-ylmethyl)guanidin, or a pharmaceutically acceptable salt thereof and combinations comprising at least one of said compounds, for use in the treatment and/or prevention of synucleinopathies.

IPC Classes  ?

• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
• A61K 31/4168 - 1,3-Diazoles having a nitrogen atom attached in position 2, e.g. clonidine
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/175 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine having the group , N—C(O)—N=N— or , e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazonesThioanalogues thereof
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention concerns screening methods to identify compounds that regulate activity of RSH enzymes such as Rel, and specifically Rel synthetase and/or Rel hydrolase activity. Also intended are compounds that interact and regulate Rel synthetase and/or hydrolase activity. These compounds are valuable to target persister cells not affected by traditional antibiotics.

IPC Classes  ?

• G16C 20/64 - Screening of libraries
• G16C 20/50 - Molecular design, e.g. of drugs
• G16B 15/30 - Drug targeting using structural dataDocking or binding prediction

Abstract

The invention provides a composite with antimicrobial activity comprising photothermal nanoparticles entrapped in a metal-organic framework and iodine. A method to prepare the iodine-based antimicrobial composite is also provided, along with polymer blends, coatings and medical devices containing the same.

IPC Classes  ?

• A01N 25/10 - Macromolecular compounds
• A01N 25/18 - Vapour or smoke emitting compositions with delayed or sustained release
• A01N 25/34 - Shaped forms, e.g. sheets, not provided for in any other group of this main group
• A01N 59/12 - Iodine, e.g. iodophorsCompounds thereof
• A01N 59/16 - Heavy metalsCompounds thereof
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof

Abstract

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 9/51 - Nanocapsules
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 35/04 - Antineoplastic agents specific for metastasis
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a system for performing measurements on a functional device (D), wherein the system comprises: - first (M1) and second (M2) apparatuses for respectively performing global and local measurements on the functional device (D), - a common support (H) for supporting the functional device (D) while performing the global and local measurements; and - an interconnection arrangement comprising a plurality of connections (C1-C8, Cb) and a plurality of contacts (T1, T2, T3, Tb) to be operatively connected to contacts (E1, E2, E3) of the functional device (D), wherein the interconnection arrangement is operatively connected to the first (M1) and second (M2) apparatuses and configured to select the first (M1) and second (M2) measurement apparatuses, or parts thereof, to operate alternately and/or simultaneously. The present invention also relates to a to a method adapted to use the system of the invention.

IPC Classes  ?

• G01R 31/26 - Testing of individual semiconductor devices
• G01Q 60/30 - Scanning potential microscopy
• G01Q 60/40 - Conductive probes

Abstract

There is provided a device for performing an assay system, the device comprising a chamber comprising a first opening, and a second opening; a liquid exit; a liquid absorbing pad adjacent to the chamber; an opening assembly for shifting the device between a closed position and an open position; a sealing element; wherein: - in the closed position the sealing element covers the liquid exit such that a liquid is prevented from flowing out of the chamber; - and in the open position at least part of the liquid exit is uncovered by the sealing element and the device comprises a fluidic path between the chamber and the liquid absorbing pad through the uncovered part of the liquid exit. There is also provided an assay system and a method for performing an assay.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

There is provided a device for performing an assay system, the device comprising a chamber comprising a first opening, and a second opening; a liquid exit; a liquid absorbing pad adjacent to the chamber; an opening assembly for shifting the device between a closed position and an open position; a sealing element; wherein: - in the closed position the sealing element covers the liquid exit such that a liquid is prevented from flowing out of the chamber; - and in the open position at least part of the liquid exit is uncovered by the sealing element and the device comprises a fluidic path between the chamber and the liquid absorbing pad through the uncovered part of the liquid exit. There is also provided an assay system and a method for performing an assay.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to a piezoelectric, epitaxially grown pseudosubstrate comprising a silicon wafer (100) having two parallel faces, and a thin layer of α-quartz (100) grown epitaxially on one of the faces of said wafer, said thin α-quartz layer (100) exhibiting a uniform crystallization with a mosaicity around the peak (100) of the quartz of between 6° and 1° and a thickness of between 100 nm and 1 μm. The present invention also relates to a process for fabricating such a pseudosubstrate, and to the use thereof for producing piezoelectric membranes.

IPC Classes  ?

• C30B 7/10 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by application of pressure, e.g. hydrothermal processes
• C30B 29/16 - Oxides
• C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
• C30B 7/02 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
• C30B 29/18 - Quartz
• C30B 33/02 - Heat treatment
• C30B 5/00 - Single-crystal growth from gels
• C30B 29/20 - Aluminium oxides

Abstract

The present invention relates to a multilayer material, comprising a solid substrate coated at least partially with a textured α-quartz buffer layer (100), the crystallographic direction [100] of the α-quartz being parallel to the crystallographic direction [100] of the silicon (100); and on said α-quartz buffer layer (100), a layer of one-dimensional epitaxial ZnO microcrystals (110) (or epitaxial ZnO microwires), said microcrystals being self-assembled. The present invention also relates to a method for producing such a multilayer material, as well as to the industrial use thereof in various technical fields.

IPC Classes  ?

• C30B 7/10 - Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by application of pressure, e.g. hydrothermal processes
• C30B 29/16 - Oxides
• C30B 29/60 - Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape

Abstract

The present invention relates to a tooth whitening composition, which comprises a reducing agent partially encapsulated in liposomes. It relates also to a method for preparing that tooth whitening composition and to the non-therapeutic cosmetic use of that composition for tooth whitening.

IPC Classes  ?

• A61K 8/14 - Liposomes
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 8/23 - SulfurSeleniumTelluriumCompounds thereof
• A61K 8/22 - PeroxidesOxygenOzone
• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

The present invention provides a polypeptide consisting of sequence SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and/or treatment of a bone disorder. The invention also provides nucleic acid sequence that encodes the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the invention may be administered in the form of a pharmaceutical composition together with at least one pharmaceutically acceptable excipient, diluent or carrier.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

The present invention provides a polypeptide consisting of sequence SEQ ID NO: 1, or a variant thereof consisting of a sequence at least 85% identical to SEQ ID NO: 1, for use in the prevention and/or treatment of a bone disorder. The invention also provides nucleic acid sequence that encodes the polypeptide, a gene construct comprising the nucleic acid sequence, or an expression vector comprising the gene construct, for said use. The polypeptide, nucleic acid sequence, gene construct, or expression vector of the invention may be administered in the form of a pharmaceutical composition together with at least one pharmaceutically acceptable excipient, diluent or carrier.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Abstract

Described herein are recombinant viral genomes comprising a nucleotide sequence encoding a telomerase reverse transcriptase (TERT) operably linked to a tissue-specific and/or organ-specific promoter. Aspects described herein may be used in the treatment of conditions associated with shortened telomere length, such as pulmonary fibrosis, myocardial infarction and conditions associated therewith.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors
• C12N 15/861 - Adenoviral vectors

Abstract

Described herein are recombinant viral genomes comprising a nucleotide sequence encoding a telomerase reverse transcriptase (TERT) operably linked to a tissue-specific and/or organ-specific promoter. Aspects described herein may be used in the treatment of conditions associated with shortened telomere length, such as pulmonary fibrosis, myocardial infarction and conditions associated therewith.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 15/861 - Adenoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to a photoinduced thermochromic or thermoluminescent composition, comprising: a) nanoparticles capable of absorbing near-infrared (NIR) radiation and converting the NIR radiation into heat, in particular metal gold nanoparticles; b) one or more phase change materials (PCM) selected from the group consisting of: b1) a PCM capable of acting as chromic or fluorochromic promoter; and b2) a PCM uncapable of acting as chromic or fluorochromic promoter; c) one or more dyes selected from the group consisting of: c1) a dye capable of modifying its colour- or emission-properties when the PCM changes between the solid state and the liquid state; and c2) a dye uncapable of modifying its colour- or emission-properties when the PCM between the solid state and the liquid state; and articles containing it. It also relates to processes for their preparation and their uses in therapy, cosmetics, diagnostics, optics and anti-fake technology.

IPC Classes  ?

• C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
• C09K 9/02 - Organic tenebrescent materials
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09D 5/22 - Luminous paints
• C09D 5/29 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes for multicolour effects
• C09D 7/41 - Organic pigmentsOrganic dyes

Abstract

Described herein is a genetically modified plant or non-human animal having reduced expression of an endogenous target gene.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding a hepatocyte nuclear factor (HNF) such as HNF1A. Aspects described herein may be used in the treatment of maturity-onset diabetes of the young (MODY).

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding a hepatocyte nuclear factor (HNF) such as HNF1A. Aspects described herein may be used in the treatment of maturity-onset diabetes of the young (MODY).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A01K 67/027 - New or modified breeds of vertebrates
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding insulin, for use in the treatment and/or prevention of neuroinflammation, neurodegeneration and/or cognitive decline, or a disease or condition associated therewith.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/28 - Insulins
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/62 - Insulins
• C12N 15/86 - Viral vectors

Abstract

The invention relates to protein particles comprising a cluster of one or more types of assembled self-contained protein, wherein the particle has a size from 50 nm to 50 micrometers; is in form of a pellet in aqueous media; is mechanically stable; and it release a particular percentage by weight of the self-contained protein within a predetermined period of time, and any other compound contained in the particle. Particular methods for obtaining the particles are also disclosed, said methods comprising the addition of salts to allow precipitation of proteins. Particular protein particles comprising lipids associated with the assembly of self-contained proteins are also disclosed. The invention also relates to several uses of the particle, in particular medical uses and to pharmaceutical and cosmetic compositions comprising the particles.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets

Abstract

They are provided gene constructs comprising a nucleotide sequence encoding the Insulin-like growth factor 1 (IGF-1) of a mammal; and target sequences of a microRNA of a tissue where the expression of IGF-1 is wanted to be prevented, wherein the sequences (a) and (b) are operationally linked to a promoter of ubiquitous expression. Also provided are expression vectors comprising the gene construct and pharmaceutical compositions comprising them. They are useful in the treatment and/or prevention of diabetes mellitus in mammals, wherein a dysfunction and/or a loss of the beta-cells of the islets of Langerhans is present.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/65 - Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/864 - Parvoviral vectors
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to methods for the production of high titer recombinant viral vectors, more particularly recombinant AAV vectors, so that the methods can be effectively employed on a scale that is suitable for the practical application of gene therapy techniques.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 7/02 - Recovery or purification

Abstract

Free-Space quantum keyless private communication method according to a communication protocol comprising exchanging information between an emitter (100) and a receiver (200) through a main quantum -classical channel and with an eavesdropper tapping said main channel through a wiretap channel, based on the wiretap channel model, wherein the overall degradation of the wiretap channel is superior than that of the main channel, comprising the steps of preparing, at the emitter (100), a message M composed of classical bits, coding said message M so as to transform it into a coded message X, practical modulating the amplitude and/or the phase of the optical pulses of the coded classical bits, sending the encoded message to the receiver (200) through a classical-quantum channel (500), such that an eavesdropper (300) tapping said channel is provided with partial information about the said states only, detecting and decoding the received message through quantum security analysis.

IPC Classes  ?

• H04B 10/112 - Line-of-sight transmission over an extended range
• H04B 10/70 - Photonic quantum communication

Abstract

Electromechanical transducer for transducing electromagnetic radiation to mechanical displacement, comprising an antenna (1a, 1b, 1c, 1d, 1e) having an electrically conductive surface (121a, 121b, 121c, 121d, 121e) and a first electrically conductive body (11a, 11b, 11c, 11d, 11e) with a first movable portion (110a, 110b, 110c, 110d, 110e), the first movable portion (110a, 110b, 110c, 110d, 110e) and said electrically conductive surface (121a, 121b, 121c, 121d, 121e) being overlapped and spaced apart by a gap, as well as configured to generate and store electric charges in its surface when receiving an electromagnetic wave, the first movable portion (110a, 110b, 110c, 110d, 110e) being as well configured to undergo a mechanical displacement due to electrostatic forces between the first movable portion (110a, 110b, 110c, 110d, 110e) and the electrically conductive surface (121a, 121b, 121c, 121d, 121e) in response to the stored electric charges.

IPC Classes  ?

• H02N 11/00 - Generators or motors not provided for elsewhereAlleged perpetua mobilia obtained by electric or magnetic means

Abstract

The invention relates to the use of cannabidiol (CBD) and/or a derivative thereof, in the treatment of mitochondrial diseases. In certain preferred embodiments, the CBD, and/or a derivative thereof is substantially devoid of tetrahydrocannabinol (THC). Moreover, the present invention also relates to a composition comprising the CBD and/or a derivative thereof and to a method of treating mitochondrial diseases in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of the CBD, a derivative thereof and/or a composition comprising thereof.

IPC Classes  ?

• A61K 31/05 - Phenols
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 39/00 - General protective or antinoxious agents

Abstract

The present invention provides new pharmaceutical co positions for the tong term treatment of diseases and specially, for use as tong term treatment of mucopolysaccharidoses type IIIA.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• C12N 9/14 - Hydrolases (3.)
• A61K 38/46 - Hydrolases (3)

Abstract

The invention relates to a device and method for vehicle-to-vehicle and vehicle-to-infrastructure communication which, from an automobile radar based on FMCW, allow the exchange of information between a vehicle and different infrastructures or between vehicles. These radars are already installed in vehicles for advanced driver assistance systems. The device comprises a signal sensing element (2) for sensing the signal emitted by the radar (1), a modulator (3) which modulates the signal sensed in the sensing element (2), and a radiant element (4) which transmits the signal modified in the modulator (3) to the radar (1). The method comprises the steps of emitting a coded signal from the radar (1) to a modulated target (6), modifying the signal in the modulated target (6) and reflecting it to the radar (1), digitising, filtering and storing the signal reflected in the modulated target (6) and generating a list of targets (6) detected.

IPC Classes  ?

• G01S 7/00 - Details of systems according to groups , ,
• G01S 13/82 - Systems using reradiation of radio waves, e.g. secondary radar systemsAnalogous systems wherein continuous-type signals are transmitted
• G01S 13/931 - Radar or analogous systems, specially adapted for specific applications for anti-collision purposes of land vehicles

Abstract

The present invention generally relates to inhibitors of ?-synuclein aggregation which are characterized by comprising an amphipathic ?-helical peptide. The invention further relates to therapeutic and diagnostic uses of such inhibitors as well as corresponding plasmonic sensors, kits, and pharmaceutical compositions.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention generally relates to inhibitors of α-synuclein aggregation which are characterized by comprising an amphipathic α-helical peptide. The invention further relates to therapeutic and diagnostic uses of such inhibitors as well as corresponding plasmonic sensors, kits, and pharmaceutical compositions.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a magnetoelectric device (D), comprising: - a magnetoelectric element (Me); and - an electric voltage source (PS) configured and arranged to induce on the magnetoelectric element (Me), at least at room temperature, ON-OFF states and OFF-ON states magnetic transitions, by applying or removing determined electric voltages, wherein at said ON state the magnetoelectric element (Me) shows permanent and net magnetization. The magnetoelectric element (Me) is configured and arranged to induce the ON-OFF states and OFF-ON states magnetic transitions by means of an ion-migration mechanism and/or a piezostrain-mediated mechanism. The present invention further relates to different uses of the magnetoelectric device of the first aspect of the present invention, including a use for implementing a data security device, and uses for information and communications technologies, including neuromorphic computing and/or stochastic data storage and/or stochastic data processing.

IPC Classes  ?

• G11C 11/15 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using thin-film elements using multiple magnetic layers
• G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
• H01L 43/08 - Magnetic-field-controlled resistors

Abstract

The present invention provides a new animal model for mucopolysaccharidosis type IVA or Morquio A syndrome and to methods of generating the animal model and uses thereof.

IPC Classes  ?

• A01K 67/0276 - Knock-out vertebrates
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for delivery of the same for treating diabetes.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for delivery of the same for treating diabetes.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a metabolic disorder, wherein the therapy involves expression of the gene construct in the central nervous system (CNS).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a central nervous system (CNS) disorder or disease, or a condition associated therewith.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 15/86 - Viral vectors
• C12N 15/861 - Adenoviral vectors

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding a fibroblast growth factor 21 (FGF21), for use in the treatment and/or prevention of a central nervous system (CNS) disorder or disease, or a condition associated therewith.

IPC Classes  ?

• A61K 38/18 - Growth factorsGrowth regulators
• C12N 15/86 - Viral vectors
• C12N 15/861 - Adenoviral vectors
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided are methods, programs and systems for eliminating noise in an image sequence produced by a method for generating images with volumetric data, using an algorithm for tracing light ray paths in participating media. Each image in the sequence comprises pixels, and the path-tracing algorithm produces path samples for each pixel. These methods comprise, for each pixel of a current image in the sequence: temporarily reprojecting the pixel according to a motion vector to obtain an average accumulated colour and a predictive model of the pixel; averaging a colour of the pixel with the average accumulated colour to obtain an updated average accumulated colour; including the updated average accumulated colour in a feature vector; and determining a final colour of the pixel by updating the predictive model according to the updated feature vector and obtaining the final colour from the updated predictive model.

IPC Classes  ?

• G06T 5/00 - Image enhancement or restoration

Abstract

An apparatus and a method using no switching elements for multiplexing and reading arrays of sensors whose electrical resistance is modulated by the signals to be measured are proposed. Sensor elements are arranged in groups and columns where each column is fed with a continuous voltage waveform of different amplitude, frequency and phase characteristics which then produce current signals that are modulated by the variable resistance signals to be measured. Modulated currents are summed row-wise and collected at the read-out circuits, either by applying a constant voltage to each row of the array or by connecting a capacitor and converting these current summations into output voltage signals. The read-out circuits de-multiplex each individual sensor signal to be measured by lock-in demodulation according to the frequencies and phases employed for the stimulation of each column.

IPC Classes  ?

• H04N 25/40 - Extracting pixel data from image sensors by controlling scanning circuits, e.g. by modifying the number of pixels sampled or to be sampled
• H03D 3/00 - Demodulation of angle-modulated oscillations
• H04N 25/74 - Circuitry for scanning or addressing the pixel array
• H04N 25/75 - Circuitry for providing, modifying or processing image signals from the pixel array
• H04N 25/76 - Addressed sensors, e.g. MOS or CMOS sensors

Abstract

The present invention concerns screening methods to identify compounds that regulate activity of RSH enzymes such as Rel, and specifically Rel synthetase and/or Rel hydrolase activity. Also intended are compounds that interact and regulate Rel synthetase and/or hydrolase activity. These compounds are valuable to target persister cells not affected by traditional antibiotics.

IPC Classes  ?

• G16C 20/64 - Screening of libraries
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12Q 1/18 - Testing for antimicrobial activity of a material
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• G16C 20/50 - Molecular design, e.g. of drugs

Abstract

The present invention relates to a compound selected from the group consisting of of N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-1-methyl-1H- pyrazol-5-yl)thiophene-2-carboxamide, [2-(2,6-dichloroanilino)-4,5-dihydroimidazol-1- yl]-phenylmethanone, 2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one, N- (diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide and 2-(1,4- dioxaspiro[4.5]decan-2-ylmethyl)guanidin, or a pharmaceutically acceptable salt thereof and combinations comprising at least one of said compounds, for use in the treatment and/or prevention of synucleinopathies.

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/4168 - 1,3-Diazoles having a nitrogen atom attached in position 2, e.g. clonidine
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides the afatinib or a pharmaceutically salt thereof for use in the treatment and/or prevention of a cancer in a patient suffering from a disease caused by a defect in DNA damage repair mechanism. Surprisingly, when afatinib was administered to FA cells, it was confirmed that there was a therapeutic anti-cancer effect without any toxic side-effect on DNA.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to a specific panel of circulating synaptic protein related miRNAs for use in the diagnosis of Mild Cognitive Impairment (MCI) and/or early diagnosis of Alzheimer's disease (AD). The invention also relates to a method and to a kit for the diagnosis of said diseases using said specific panel of circulating miRNAs biomarkers.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A01K 67/027 - New or modified breeds of vertebrates
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• C07K 1/00 - General processes for the preparation of peptides
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C07K 19/00 - Hybrid peptides
• C12N 15/12 - Genes encoding animal proteins
• C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof

Abstract

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

IPC Classes  ?

• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a photoinduced thermochromic or thermoluminescent composition, comprising: a) nanoparticles capable of absorbing near-infrared (NIR) radiation and converting the NIR radiation into heat, in particular metal gold nanoparticles; b) one or more phase change materials (PCM) selected from the group consisting of: b1) a PCM capable of acting as chromic or fluorochromic promoter; and b2) a PCM uncapable of acting as chromic or fluorochromic promoter; c) one or more dyes selected from the group consisting of: c1) a dye capable of modifying its colour- or emission- properties when the PCM changes between the solid state and the liquid state; and c2) a dye uncapable of modifying its colour- or emission- properties when the PCM between the solid state and the liquid state; and articles containing it. It also relates to processes for their preparation and their uses in therapy, cosmetics, diagnostics, optics and anti-fake technology.

IPC Classes  ?

• C09K 9/02 - Organic tenebrescent materials
• B41M 3/14 - Security printing
• A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes

Abstract

The present invention relates to a tooth whitening composition, which comprises a reducing agent partially encapsulated in liposomes. It relates also to a method for preparing that tooth whitening composition and to the non-therapeutic cosmetic use of that composition for tooth whitening.

IPC Classes  ?

• A61K 8/14 - Liposomes
• A61K 8/22 - PeroxidesOxygenOzone
• A61K 8/24 - PhosphorusCompounds thereof
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61Q 11/02 - Preparations for deodorising, bleaching or disinfecting dentures

Abstract

The present invention relates to a tooth whitening composition, which comprises a reducing agent partially encapsulated in liposomes. It relates also to a method for preparing that tooth whitening composition and to the non-therapeutic cosmetic use of that composition for tooth whitening.

IPC Classes  ?

• A61K 8/14 - Liposomes
• A61K 8/22 - PeroxidesOxygenOzone
• A61K 8/24 - PhosphorusCompounds thereof
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61Q 11/02 - Preparations for deodorising, bleaching or disinfecting dentures

Abstract

The present invention relates to a chipless RFID tag (T), comprising: —a dielectric substrate (1); and —electromagnetic resonators (3) excitable by an external electromagnetic field and respectively arranged on separate spatial locations of the dielectric substrate (1) forming a row, and configured to resonate at a common resonant frequency. The dielectric substrate (1) defines several predetermined encoding areas that include the separate spatial locations, so that data is encoded by the presence/absence of operative electromagnetic resonators (3) thereon. The present invention also relates to a system comprising the chipless RFID tag of the invention and a RFID reader (R) reading an encoded code by detecting the presence/absence of attenuation peaks on an electromagnetic wave providing the external electromagnetic field to the electromagnetic resonators (3). The present invention also relates to a method for encoding data on a chipless RFID tag defined according to the present invention.

IPC Classes  ?

• G06K 7/10 - Methods or arrangements for sensing record carriers by electromagnetic radiation, e.g. optical sensingMethods or arrangements for sensing record carriers by corpuscular radiation
• G06K 19/077 - Constructional details, e.g. mounting of circuits in the carrier

Abstract

The present invention relates to compounds of formula (I): AA1-AA2-D-Ile-AA3-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 25/06 - Antimigraine agents
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

Bacillus thuringensisBacillus thuringensis; and c) operating the system with the developed two-step aeration protocol in order to obtain a fermented solid enriched with biopesticides.

IPC Classes  ?

• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• A01N 63/23 - B. thuringiensis

Abstract

The present invention relates to compounds of formula (I): AA1-AA2-D-Ile-AA322 or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+cells are provided as well.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61P 31/14 - Antivirals for RNA viruses
• A61P 35/00 - Antineoplastic agents
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding insulin, for use in the treatment and/or prevention of neuroinflammation, neurodegeneration and/or cognitive decline, or a disease or condition associated therewith.

IPC Classes  ?

• A61K 38/28 - Insulins
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Described herein is a gene construct comprising a nucleotide sequence encoding insulin, for use in the treatment and/or prevention of neuroinflammation, neurodegeneration and/or cognitive decline, or a disease or condition associated therewith.

IPC Classes  ?

• A61K 38/28 - Insulins
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The invention relates to protein particles comprising a cluster of one or more types of assembled self-contained protein, wherein the particle has a size from 50 nm to 50 micrometers; is in form of a pellet in aqueous media; is mechanically stable; and it release a particular percentage by weight of the self-contained protein within a predetermined period of time, and any other compound contained in the particle. Particular methods for obtaining the particles are also disclosed, said methods comprising the addition of salts to allow precipitation of proteins. Particular protein particles comprising lipids associated with the assembly of self-contained proteins are also disclosed. The invention also relates to several uses of the particle, in particular medical uses and to pharmaceutical and cosmetic compositions comprising the particles.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/14 - Particulate form, e.g. powders
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C02F 1/14 - Treatment of water, waste water, or sewage by heating by distillation or evaporation using solar energy
• C07K 1/00 - General processes for the preparation of peptides
• C07K 1/02 - General processes for the preparation of peptides in solution
• C07K 2/00 - Peptides of undefined number of amino acidsDerivatives thereof
• C07K 4/00 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 19/00 - Hybrid peptides

Abstract

The invention relates to protein particles comprising a cluster of one or more types of assembled self-contained protein, wherein the particle has a size from 50 nm to 50 micrometers; is in form of a pellet in aqueous media; is mechanically stable; and it release a particular percentage by weight of the self-contained protein within a predetermined period of time, and any other compound contained in the particle. Particular methods for obtaining the particles are also disclosed, said methods comprising the addition of salts to allow precipitation of proteins. Particular protein particles comprising lipids associated with the assembly of self-contained proteins are also disclosed. The invention also relates to several uses of the particle, in particular medical uses and to pharmaceutical and cosmetic compositions comprising the particles.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

The present invention relates to methods for the production of high titer recombinant viral vectors, more particularly recombinant AAV vectors, so that the methods can be effectively employed on a scale that is suitable for the practical application of gene herapy techniques.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 7/02 - Recovery or purification
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to methods for the production of high titer recombinant viral vectors, more particularly recombinant AAV vectors, so that the methods can be effectively employed on a scale that is suitable for the practical application of gene herapy techniques.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors
• C12N 7/02 - Recovery or purification

Abstract

The present invention refers to a process for polymerizing benzoxazine by irradiation of a mixture of a benzoxazine compound, comprising a group including an aryl group, and a catalyst, with light from a wavelength comprised from 450nm to 700nm. It refers also to the polymerized benzoxazine compound obtainable according to that process, and to its use.

IPC Classes  ?

• C08G 73/02 - Polyamines
• C08G 14/06 - Condensation polymers of aldehydes or ketones with two or more other monomers covered by at least two of the groups of aldehydes with phenols and monomers containing hydrogen attached to nitrogen
• C08L 79/02 - Polyamines